

Synthesis of Pyrrolidine or Piperidine Ring-fused Azepino[5,4,3-*cd*]indole Derivatives

Yong Sup Lee*, Byung Joon Min*, Yong Kyu Park[†], Jae Yeol Lee, Sook Ja Lee[†], and Hokoon Park


Division of Applied Science, Korea Institute of Science & Technology, P.O. Box 131 Cheongryang, Seoul 130-650, Korea

[†]Department of Chemistry, Hankuk University of Foreign Studies, Yong-in 449-791, Korea


Received 2 April 1999; revised 24 May 1999; accepted 28 May 1999

Abstracts: The synthesis of pyrrolidine or piperidine ring-fused 2-phenyl-azepino[5,4,3-*cd*]indole derivatives (**2**) has been accomplished through the *N*-acyliminium ion cyclization of hydroxy- or alkoxylactams (**5**) derived from cyclic anhydrides or chiral hydroxy acids. © 1999 Elsevier Science Ltd. All rights reserved.


Azepino[5,4,3-*cd*]indole is an interesting heterocycle and forms the skeleton of clavicipitic acid, a derailment product of normal ergot metabolism.¹ Recently, considerable efforts have been devoted to the synthesis of azepino[5,4,3-*cd*]indole derivatives due to their unusual structures and potential biological activities.^{2–6} Subsequently, several azepino[5,4,3-*cd*]indole derivatives have been prepared and some of them have been found to possess α_2 -adrenoceptor, 5-HT_{1A}, or dopamine D₂ receptor affinity.^{3,4} However, there is no report on the synthesis of pyrrolidine or piperidine ring-fused azepino[5,4,3-*cd*]indoles.



Clavicipitic acid



1




2

The usual synthesis of azepino[5,4,3-*cd*]indole derivatives have been achieved by a prior functionalization at the 4-position of indole nucleus followed by the ring closure to form azepine ring.² Although the direct cyclizations at the 4-position of indole nucleus through iminium ion intermediate have been published, these methods use only a limited example of iminium or acyliminium ion precursors, which were usually derived from formaldehyde or formaldehyde congener and tryptamines.^{5,6} Furthermore, tryptamine rings without electron donating group or with electron withdrawing group were unreactive toward cyclization with formaldehyde under normal or drastic conditions.⁵ At this point, we thought that *N*-acyliminium ion cyclization strategy would be more useful in the synthesis of azepino[5,4,3-*cd*]indole derivatives, since *N*-acyliminium ion intermediate can be

reacted with a broad range of nucleophiles due to the higher reactivity than that of iminium ion intermediate.⁷











In continuation with our efforts on the synthesis of pharmacologically active compounds,⁸⁻⁹ we have developed a synthetic method on the synthesis of new type of azepino[5,4,3-*cd*]indole system through several *N*-acyliminium ion intermediate. In this communication, we wish to report the synthesis of pyrrolidine or piperidine ring-fused 2-phenylazepino[5,4,3-*cd*]indole derivatives (**2**) through the *N*-acyliminium ion intermediate (**6**) derived from hydroxy- or alkoxy lactams as illustrated in Scheme 1. This synthesis would be very useful to obtain diverse molecules for the study of structure-activity relationships since several series of 2-aryl substituted indol-3-yl-ethylamines,¹⁰ 2-aryl substituted benzothiophen-3-yl-ethylamines and 2-aryl substituted benzofuran-3-yl-ethylamines¹¹ could be used as starting compounds.



Scheme 1

The phthalimide group in **3c** (X=H)¹⁰ was removed by treatment of hydrazine hydrate in refluxing ethanol to provide **4** in 85% yield. (2-Phenylindol-3-yl)ethylamine (**4**) was condensed with succinic anhydride or glutaric anhydride in refluxing xylene to afford cyclic imides **3a** and **3b** in 45% and 75% yields, respectively. For the synthesis of optically pure pyrrolidino-azepino-indole derivatives, compound **4** was condensed with L-malic acid or L-tartaric acid in refluxing xylene to provide **3d** ($[\alpha]_D^{22} = -29.8$, c 0.85, MeOH) and **3e** ($[\alpha]_D^{22} = +33.6$, c 0.75, MeOH) in 43% and 45% yields, respectively. We first tried reduction of succinimide **3a** with $NaBH_4$ in MeOH or in EtOH in the presence of *conc*- H_2SO_4 system⁸ but the reduction was not completed unexpectedly while most of starting material was recovered. However,

Table 1. Reduction of Cyclic Imides (**3a** ~ **3e**) and Cyclization Reaction of Lactams (**5a** ~ **5e**)

Starting Compd	Condition A	Product (5) (Yield)	Condition B	Product (2) (Yield)
3a	DIBAH, -78 - 0°C	 5a (69%)	HCO ₂ H, reflux	 2a (78%)
3b	DIBAH, -78 - 0°C	 5b (60%)	HCO ₂ H, reflux	 2b (73%)
3c	DIBAH, -78 - 0°C	 5c (62%)	HCO ₂ H, reflux	 2c (60%)
3d	1. NaBH ₄ , 1M H ₂ SO ₄ EtOH, 0°C - rt 2. Ac ₂ O, NEt ₃ CH ₂ Cl ₂ , rt	 5d (60%)	1. HCO ₂ H, reflux 2. AcCl, EtOH, rt	 2d (67%)
3e	1. NaBH ₄ , 1M H ₂ SO ₄ EtOH, 0°C - rt 2. Ac ₂ O, NEt ₃ CH ₂ Cl ₂ , rt	 5e (73%)	1. HCO ₂ H, reflux 2. AcCl, EtOH, rt	 2e (62%)

the reduction of **3a** with 2 equivalents of DIBAH proceeded smoothly to furnish hydroxylactam **5a** in 69% yield (Table 1). The reduction of glutarimide **3b** and phthalimide **3c** at the same condition also afforded hydroxylactams **5b** and **5c** in 60% and 62% yields, respectively. On the other hand, the reduction of (3*S*)-3-hydroxysuccinimide **3d** with DIBAH gave the reduced products as nearly 1:1 mixture of regioisomers even at low temperature (−78 °C). Fortunately, the NaBH₄ reduction (*conc*-H₂SO₄/EtOH) produced regioselectively the 5-ethoxy-4-hydroxylactam in good yield.^{8a} Thus, the reduction of **3d** and **3e** in this condition followed by protection of the hydroxyl groups of the reduced products as acetates provided **5d** and **5e** in 60% and 73% yields for two steps, respectively.

Finally, hydroxylactams (**5a**, **5b**, **5c**) and chiral ethoxylactams (**5d**, **5e**) were subjected to the *N*-acyliminium ion cyclization condition to form azepino[5,4,3-*cd*]indole ring. The cyclization reactions in refluxing formic acid proceeded cleanly in all cases to provide pyrrolidino- and piperidino-azepino[5,4,3-*cd*]indole derivatives in good yields (60 ~ 78%). The cyclization products **2d** ($[\alpha]_D^{22} = +70.9$, *c* 0.75,

MeOH) and **2e** ($[\alpha]_D^{22} = -56.8$, c 0.50, MeOH) were also obtained in diastereomerically pure forms in accordance with our previous results by treatment of chiral ethoxylactams (**5d**, **5e**) with formic acid followed by deprotection of acetyl group (AcCl/EtOH).⁸ The structures of cyclization products were readily confirmed by the comparison of ¹H NMR spectra of **5a** and **2a**.^{12,13} The signal of H-4 (indole numbering) at 7.65 ppm (d, $J=7.71$ Hz) in hydroxylactam **5a** was disappeared and the coupling pattern of the signal of H-5 at 7.11 ppm (t, $J=7.35$ Hz) was changed from *triplet* to *doublet* (6.95 ppm, d, $J=7.41$ Hz) without changing coupling pattern of 2-phenyl substituent in the ¹H NMR spectrum of the cyclized product **2a**. These spectral data show that the cyclization proceeded through the capture of *N*-acyliminium ion intermediate by the 4-position of indole nucleus resulting in the formation of azepino[5,4,3-*cd*]indole ring.

Acknowledgment. This work was supported by the Ministry of Science and Technology, Korea

References and Notes

- (a) P. A. Stadler and P. Stütz, *The Alkaloids: The Ergot Alkaloids*, Vol. 15. Ed. by R. H. F. Manske, Academic Press Inc., London, 1975, pp. 1-40. (b) Robbers, J. E.; Otsuka, H.; Floss, H. G.; Arnold, E. V.; Clardy, G. J. *Org. Chem.* **1980**, *45*, 1117.
- (a) Kozikowski, A. P.; Greco, M. N. *J. Org. Chem.* **1984**, *49*, 2310. (b) Harrington, P. J.; Hegedus, L. S.; McDaniel, K. F. *J. Am. Chem. Soc.* **1987**, *109*, 4335. (c) Iwao, M.; Ishibashi, F. *Tetrahedron* **1997**, *53*, 51. (d) Yokoyama, Y.; Matsumoto, T.; Murakami, Y. *J. Org. Chem.* **1995**, *60*, 1486, and references cited therein.
- Clark, R. D.; Weinhardt, K. K.; Berger, J.; Fisher, L. E.; Brown, C. M.; MacKinnon, A. C.; Kilpatrick, A. T.; Spedding, M. J. *Med. Chem.* **1990**, *33*, 633.
- Gmeiner, P.; Sommer, J.; Hoefner, G. *Arch. Pharm.* **1995**, *328*, 329.
- Novák, L.; Hanania, M.; Kovács, P.; Rohály, J.; Kolonits, P.; Szántay, C. *Heterocycles* **1997**, *45*, 2331.
- Nakatsuka, S.-i.; Miyazaki, H.; Goto, T. *Chem. Lett.* **1981**, 407.
- H. Hiemstra and W. N. Speckamp, *Addition to N-Acyliminium Ions*. In *Comprehensive Organic Chemistry*; Trost, B. M., Fleming, I., Eds.; Pergamon Press: New York, 1991; Vol. 2, pp 1047-1082.
- (a) Lee, Y. S.; Kang, D. W.; Lee, S. J.; Park, H. *Synth. Commun.* **1995**, *25*, 1947. (b) Lee, Y. S.; Kang, D. W.; Lee, S. J.; Park, H. *J. Org. Chem.* **1995**, *60*, 7149.
- (a) Lee, J. Y.; Lee, Y. S.; Chung, B. Y.; Park, H. *Tetrahedron* **1997**, *53*, 2449. (b) Lee, Y. S.; Kim, D. W.; Lee, J. Y.; Park, H. *Bull. Korean Chem. Soc.* **1998**, *19*, 814. (c) Kim, J. H.; Lee, Y. S.; Park, H.; Kim, C. S. *Tetrahedron* **1998**, *54*, 7395.
- Liao, Y.; Kozikowski, A. P.; Guidotti, A.; Costa, E. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 2099.
- Chu, L.; Fisher, M. H.; Goulet, M. T.; Wyvratt, M. J. *Tetrahedron Lett.* **1997**, *38*, 3871.
- Data for **5a**: mp 134 ~ 135 °C; IR (KBr) 3288, 2934, 1668, 1458 cm⁻¹; ¹H NMR(300 MHz, CDCl₃) δ 8.35(1H, s), 7.65(1H, d, $J=7.7$ Hz), 7.59(1H, d, $J=13.6$ Hz), 7.41(2H, t, $J=7.7$ Hz), 7.26-7.36(2H, m), 7.19(1H, t, $J=7.9$ Hz), 7.11(1H, t, $J=7.4$ Hz), 4.83(1H, d, $J=4.4$ Hz), 3.69(1H, m), 3.43-3.51(2H, m), 3.25(1H, m), 3.11(1H, m), 2.33(1H, m), 2.10(2H, m), 1.65(1H, m); ¹³C NMR(75 MHz, CDCl₃) δ 174.9, 135.9, 135.1, 132.9, 127.9(2), 126.7(2), 123.8, 122.5, 119.9, 118.9(2), 111.1, 110.1, 83.91, 40.00, 29.20, 28.25, 23.18; MS (m/z ; rel. intensity, %) 302(M⁺-H₂O, 16), 219(56), 206(100), 191(2), 178(15), 151(1), 102(2), 89(1), 77(4).
- Data for **2a**: mp 234 ~ 235 °C; IR (KBr) 3268, 3056, 2924, 2362, 1662 cm⁻¹; ¹H NMR (300 MHz, CDCl₃) δ 8.64(1H, s), 7.54(2H, d, $J=7.6$ Hz), 7.46(2H, t, $J=7.5$ Hz), 7.26-7.40(2H, m), 7.20(1H, t, $J=7.7$ Hz), 6.95(1H, d, $J=7.4$ Hz), 5.24(1H, t, $J=7.4$ Hz), 4.37(1H, dt, $J=12.9, 3.2$ Hz), 3.38(1H, td, $J=12.4, 3.0$ Hz), 3.21(1H, t, $J=12.9$ Hz), 3.05(1H, br d, $J=15.6$ Hz), 2.77(1H, m), 2.50(2H, t, $J=7.9$ Hz), 2.24(1H, m); ¹³C NMR(75 MHz, CDCl₃) δ 174.9, 136.8, 136.2, 134.2, 132.8, 128.8(2), 127.9(2), 127.7, 125.4, 122.2, 116.8, 111.5, 109.5, 63.80, 43.13, 30.60, 28.32, 28.20; MS (m/z ; rel. intensity, %) 302(M⁺, 94), 301(100), 286(17), 272(4), 258(6), 245(21), 242(20), 229(26), 216(15), 203(8), 188(4), 175(2), 164(3), 151(11), 139(4), 126(9), 114(12), 101(4), 87(3), 54(4); HRMS (EI) Calcd for C₂₀H₁₈N₂O: (M⁺) m/z 302.1419. Found: 302.1419.